ReviewBritish journal of cancer2023
Proactive breast cancer risk assessment in primary care: a review based on the principles of screening.
Review in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Understanding the contribution of lifestyle in breast cancer risk prediction: a systematic review of models applicable to Europe.BMC cancer · 2023Pooled it
- Understanding patient perspectives on breast cancer risk: a qualitative study to inform genetic testing communication in the primary care setting.Journal of community genetics · 2026Article
- The breast cancer risk assessment pathway in England: a systems analysis of current challenges and ways to improve.British journal of cancer · 2026Article
- Acceptability of breast cancer risk assessment for women aged 30-49: Views of women from six under-served groups.PloS one · 2026Article
- Primary care online training on multifactorial breast cancer risk: pre-post evaluation study.BJGP open · 2025Article
- Evaluation of a telehealth service to support breast cancer prevention medication uptake: a protocol of a mixed methods study.BMJ open · 2025Article
- A Scoping Review of Primary Breast Cancer Risk Reduction Strategies in East and Southeast Asia.Cancers · 2025Review
- CanRisk-GP protocol: A feasibility study of incorporating proactive multifactorial breast cancer risk assessment into general practice.PloS one · 2025Article
- Do women with a history of breast cancer recommend risk-based breast cancer screening? An in-depth interview study.Frontiers in psychology · 2025Article
- Article
- Article
- Digital innovation for cancer risk assessment allows large-scale service redevelopment of regional cancer genetics service delivery.Familial cancer · 2024Article
- Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.British journal of cancer · 2024Review
- Risk-Stratified Breast Cancer Screening in Malaysia: Challenges and Opportunities.Asian Pacific journal of cancer prevention : APJCP · 2024Review
- Multicancer screening test based on the detection of circulating non haematological proliferating atypical cells.Molecular cancer · 2024Article
- Patterns of referrals to regional clinical genetics services for women potentially at above-population level risk of breast cancer.BJC reports · 2024Article
- Article
- Implementation of risk assessment process for breast cancer risk in primary care.Journal of cancer prevention & current research · 2024Article
- Article
- Proactive familial cancer risk assessment: a service development study in UK primary care.BJGP open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the UK, the National Institute for Health and Care Excellence (NICE) recommends that women at moderate or high risk of breast cancer be offered risk-reducing medication and enhanced breast screening/surveillance. In June 2022, NICE withdrew a statement recommending assessment of risk in primary care only when women present with concerns. This shift to the proactive assessment of risk substantially changes the role of primary care, in effect paving the way for a primary care-based screening programme to identify those at moderate or high risk of breast cancer. In this article, we review the literature surrounding proactive breast cancer risk assessment within primary care against the consolidated framework for screening. We find that risk assessment for women under 50 years currently satisfies many of the standard principles for screening. Most notably, there are large numbers of women at moderate or high risk currently unidentified, risk models exist that can identify those women with reasonable accuracy, and management options offer the opportunity to reduce breast cancer incidence and mortality in that group. However, there remain a number of uncertainties and research gaps, particularly around the programme/system requirements, that need to be addressed before these benefits can be realised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.